Clinical Trial Update: Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update on preemptive use of convalescent plasma for high-risk COVID-19 patients, status not yet determined.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Covid19
• Immunodeficiency
• Old Age Debility

Drugs mentioned

• Convalescent Plasma (convalescent plasma)

Snippet

Sponsor: University Hospital, Geneva | Conditions: Covid19, Immuno-Deficiency | Phase 3 | Status: UNKNOWN